Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
Sheng-Mou Hsiao, Chun-Hou Liao, Ho-Hsiung Lin, Hann-Chorng Kuo
Int Neurourol J. 2015;19(3):171-177.   Published online 2015 Sep 22
DOI: https://doi.org/10.5213/inj.2015.19.3.171
Citations to this article as recorded by
  Crossref logo
Is mirabegron equally as effective when used as first- or second-line therapy in women with overactive bladder?
Maurizio Serati, Umberto Leone Roberti Maggiore, Paola Sorice, Simona Cantaluppi, Enrico Finazzi Agrò, Fabio Ghezzi
International Urogynecology Journal.2017; 28(7): 1033.     CrossRef
VAISTŲ, VARTOJAMŲ DIRGLIOSIOS ŠLAPIMO PŪSLĖS SINDROMO GYDYMUI, EFEKTYVUMO PALYGINIMAS
Vita Kvekšaitė, Ieva Vasilavičiūtė, Monika Zinkevičiūtė, Povilas Aniulis, Rosita Aniulienė
Sveikatos mokslai.2017; 27(3): 27.     CrossRef
Oral pharmacological therapy for urinary incontinence
Dae Kyung Kim
Journal of the Korean Medical Association.2016; 59(3): 215.     CrossRef
High satisfaction with direct switching from antimuscarinics to mirabegron in patients receiving stable antimuscarinic treatment
Chun-Hou Liao, Hann-Chorng Kuo
Medicine.2016; 95(45): e4962.     CrossRef